Clinical trials: Myocardial Infarct
Stem Cell Transplantation, Ventricular Dysfunction, Left
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
Heart attacks are a leading cause of death in both men and women in the United States. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly…
- Trial name
- PROMETHEUS (NCT00587990)
- Testing
- Lower dose mesenchymal stem cell (MSC) injection, Higher dose MSC injection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Joshua M Hare
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)
Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
The goal of this proposal is to test the implementation of an innovative approach to improving health and lowering cost for a high risk population of patients with acute myocardial infarction (AMI) immediately…
- Trial name
- Heartstrong (NCT01800201)
- Testing
- Electronic Pill Bottle, Incentives, Social Influence
- Where
- United States
- Volunteers
- 1,509 people
- Sponsor
- University of Pennsylvania
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack.
- Trial name
- NCT00684060
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cardiovascular Diseases, Cardiovascular Abnormalities
The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada.
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Heart Attack, Stroke
- Trial name
- NCT03826914
- Testing
- CardioFlex Q10
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Myocardial Infarction
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI).
- Trial name
- VORA-PRATIC (NCT02545933)
- Testing
- Prasugrel, Vorapaxar, Aspirin
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Florida
Acute Myocardial Infarction, Pacing Therapy
Post-Myocardial Infarction Remodeling Prevention Therapy
The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial…
- Conditions
- Acute Myocardial Infarction, Pacing Therapy, Cardiac Remodeling, Heart Failure
- Trial name
- PRomPT (NCT01213251)
- Testing
- Single Site Pacing, Dual Site Pacing
- Where
- 26 sites in United States, Denmark and 5 more
- Volunteers
- 129 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Myocardial Infarction
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.
- Trial name
- EMMY (NCT03087773)
- Testing
- Empagliflozin 10 mg
- Where
- 11 sites in Austria
- Volunteers
- 476 people
- Sponsor
- Medical University of Graz
Acute Myocardial Infarction
ClearWay Rx Readmission Registry
The purpose of this registry is to determine if delivery of weight adjusted, in a large dose with either Abcixmab or Eptifibitide through the ClearWay™ RX, in patients admitted for primary coronary intervention lowers readmission…
- Trial name
- ClearWay (NCT01673893)
- Testing
- ClearWay™ Rx catheter
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Cardiovascular Institute of the South Clinical Research Corporation
Myocardial Infarction
Risk Stratification in Patients With Preserved Ejection Fraction
The purpose of the study is to assess the prevalence and the prognostic value of non-invasive indexes and programmed ventricular stimulation for sudden cardiac death in post-myocardial infarction (MI) patients with left…
- Trial name
- PRESERVE-EF (NCT02124018)
- Testing
- Programmed ventricular stimulation, ICD implantation
- Where
- Greece
- Volunteers
- 575 people
- Sponsor
- University of Athens
Cardiomyopathy, Coronary Artery Disease
Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly
The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death in patients 70 years and older.
- Conditions
- Cardiomyopathy, Coronary Artery Disease, Congestive Heart Failure, Myocardial Infarction
- Trial name
- I-70 (NCT02121158)
- Testing
- Implantable Cardioverter Defibrillator, Optimal Medical Therapy
- Where
- 5 sites in United States
- Volunteers
- 167 people
- Sponsor
- VA Office of Research and Development
Coronary Artery Disease, Myocardial Infarction
PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril
This non-interventional, ambispective study was aimed at evaluating the effectiveness, safety, and tolerability of bisoprolol and perindopril SPC in previous myocardial infarction patients with HTN and CAD treated with the drug…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Arterial Hypertension
- Trial name
- PRIDE (NCT04656847)
- Testing
- in daily everyday routine practice
- Where
- Russia
- Volunteers
- 504 people, healthy volunteers welcome
- Sponsor
- Servier Russia
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Myocardial Infarction
APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Reocclusion of the infarct artery is observed in about 30% of patients within three months after successful thrombolysis for acute myocardial infarction (MI).
- Trial name
- NCT00138034
- Testing
- Percutaneous coronary intervention (PCI)
- Where
- Netherlands
- Volunteers
- 49 people
- Sponsor
- Heartcenter, University Medical Center St. Radboud
Myocardial Infarction
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood…
- Trial name
- NCT00046228
- Where
- 227 sites in United States, Argentina and 17 more
- Volunteers
- 2,461 people
- Sponsor
- Centocor, Inc.
Myocardial Infarction, Death
Relation Between NLR and IMR in STEMI Patients
The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker for atherosclerotic process and predictor for clinical outcomes in patients with various cardiovascular diseases.
- Trial name
- NCT02828137
- Volunteers
- 123 people
- Sponsor
- Inha University Hospital
Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation
ACCESS to the Cardiac Cath Lab in Patients Without STEMI Resuscitated From Out-of-hospital VT/VF Cardiac Arrest
To determine if survival to hospital discharge with good neurological outcome for adults ages 18-75 who are resuscitated from out-of-hospital VT/VF cardiac arrest without clinical signs of a heart attack do better by going…
- Conditions
- Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation, Cardiopulmonary Arrest With Successful Resuscitation
- Trial name
- NCT03119571
- Testing
- Initial CCL admission, Initial ICU admission
- Where
- 23 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- University of Minnesota
ISCHEMIC CARDIOMYOPATHY
Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease
The investigator hopes to introduce a novel MRI contrast agent with SeeMore ™ that directly defines viable myocardium. Identifying viable myocardium non-invasively using cardiac MRI is still a moving target and a question we plan…
- Trial name
- NCT01989195
- Testing
- 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University